Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study).

Trial Profile

Assessing the Effect of Missing Doses (Off-Days) of Daily Medication in Patients Stable on Pharmacotherapy for ADHD Receiving Atomoxetine or OROS Methylphenidate: A Parallel Matched Group Clinical Study (On/Off Study).

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 04 Dec 2012

At a glance

  • Drugs Atomoxetine; Methylphenidate
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms EMD
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Jun 2012 Actual patient number is 23 according to ClinicalTrials.gov.
    • 06 Jun 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 01 Jul 2010 Actual initiation date added to 1 Jun 2010 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top